pharma · Narcolepsy and Idiopathic Hypersomnia · Narcolepsy Type 1 · CNTA
Centessa Pharmaceuticals
Centessa Pharmaceuticals plc
Centessa Pharmaceuticals clinical programs — 7 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- 1 Ashley Road, Cheshire, WA14 2DT, United Kingdom, GB
- Founded
- 2021
- Employees
- 142
- Programs
- 15
- Drugs
- 11
- Patents
- 7
Centessa Pharmaceuticals projects
7 ClinicalTrials.gov programs sponsored by Centessa Pharmaceuticals.
Centessa Pharmaceuticals has 7 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
Imgatuzumab
Centessa Pharmaceuticals plc
Cutaneous Squamous Cell Carcinoma
1 trial -
LB101
Centessa Pharmaceuticals plc
Advanced Solid Tumor
1 trial -
LB101-101
Centessa Pharmaceuticals plc
Advanced solid tumors
1 trial -
ORX750
Centessa Pharmaceuticals plc
Narcolepsy Type 1
2 trials -
ORX750-0201
Centessa Pharmaceuticals plc
Narcolepsy and Idiopathic Hypersomnia
1 trial -
ORX750-202
Centessa Pharmaceuticals plc
Narcolepsy and Idiopathic Hypersomnia
1 trial -
SerpinPC
Centessa Pharmaceuticals plc
Hemophilia B with Inhibitor
1 trial
Frequently asked questions
How many clinical projects does Centessa Pharmaceuticals have?
7 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.